<DOC>
	<DOCNO>NCT00784823</DOCNO>
	<brief_summary>The purpose study determine tolerance potential efficacy combine dose intense melphalan escalate dos bortezomib patient multiple myeloma undergo autologous stem cell transplantation .</brief_summary>
	<brief_title>Study Combining Bortezomib With High Dose Melphalan Treat Multiple Myeloma</brief_title>
	<detailed_description>Multiple myeloma second common hematological malignancy affect approximately 40,000 Americans.Conventional chemotherapy achieve limited control disease study report improved response rate patient treat dose-intense therapy autologous hematopoietic stem cell transplantation . This Phase I/II study investigate potential combination therapy dose-intense melphalan escalate dos bortezomib .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>1 . A confirmed diagnosis multiple myeloma 2 . Show progression disease previous cycle doseintense melphalan , le 25 % decrease paraprotein measure 8 week prior cycle doseintense melphalan May receive intervene therapy disease progression doseintense melphalan enrollment protocol 3 . Age:18yrs76yrs time melphalan administration 4 . Gender : There gender restriction 5 . Availability &gt; 2x10^6 autologous peripheral blood CD34+ cells/kg syngeneic donor meeting eligibility criterion syngeneic donation Syngeneic transplantation prefer For patient enrolled phase I part study , &gt; 1x10^6 autologous syngeneic peripheral blood CD34+ cells/kg remain storage `` backup '' case engraftment failure 6 . Recovery complication salvage therapy , administer 1 . Diagnosis multiple myeloma 2 . Chemotherapy radiotherapy within 28 day initiate treatment study 3 . Prior doseintense therapy within 56 day initiate treatment study 4 . Uncontrolled bacterial , viral , fungal parasitic infection 5 . Uncontrolled CNS metastases 6 . Known amyloid deposition heart 7 . Organ dysfunction LVEF &lt; 40 % cardiac failure responsive therapy FVC , FEV1 , DLCO &lt; 50 % predict and/or receive supplementary continuous oxygen Evidence hepatic synthetic dysfunction , total bilirubin &gt; 2x AST &gt; 3x ULN Measured creatinine clearance &lt; 20ml/min Sensory peripheral neuropathy grade 4 8 . Karnofsky score &lt; 70 % unless result bone disease directly cause myeloma 9 . Life expectancy limit another comorbid illness 10 . History another malignancy remission &lt; 2yrs ( basal cell carcinoma ) 11 . Pregnant ( woman ) unwilling use acceptable birth control method ( men woman ) twelve month treatment 12 . Documented hypersensitivity melphalan bortezomib component formulation 13 . Patients unable unwilling provide consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>